This is easier to achieve if the cancer is driven by a clearly defined mutation or amplification e.g. pancreatic cancer (KRAS mutation), colon cancers (mutations in APC or WNT pathway), squamous cell skin cancer (p53 mutations), HER2 positive breast cancer (amplification of HER2). Here, ERBB2 is linked to malignant colon neoplasm.